ABT-751 (E7010)

ABT-751 (E7010) binds to the colchicine site on β-tubulin and inhibits polymerization of microtubules, not a substrate for the MDR transporter and is active against cell lines resistant to vincristine, doxorubicin, and cisplatin. Phase 1/2.

ABT-751 (E7010)化学構造

CAS No. 141430-65-1

サイズ 価格(税別) 在庫状況
10mM (1mL in DMSO) JPY 28500 国内在庫あり
JPY 21900 国内在庫あり
JPY 80000 国内在庫あり

代表番号: 045-509-1970|電子メール:[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例(5)

カスタマーフィードバック3个实验数据

製品安全説明書

現在のバッチを見る: S116501 DMSO] 74 mg/mL] false] Ethanol] 12 mg/mL] false] Water] Insoluble] false 純度: 99.95%
99.95

ABT-751 (E7010)関連製品

Microtubule Associated阻害剤の選択性比較

Cell Data

Cell Lines Assay Type Concentration Incubation Time 活性情報 PMID
HUVEC Function assay 100-1000 nM 4 h Induction of vascular disrupting activity in HUVEC assessed as VEGF-induced tube formation at 100 to 1000 nM after 4 hrs by microscopic analysis 24106982
P388 cell line Function assay 72 h Effective concentration to inhibit cell proliferation by 50% relative to untreated control cell after 72 hr of continuous exposure in P388 cell line, IC50=0.19 μM 12383017
P388/4.0 r-M cell line Function assay 72 h Effective concentration to inhibit cell proliferation by 50% relative to untreated control cell after 72 hr of continuous exposure in P388/4.0 r-M cell line, IC50=15 μM 12383017
HeLa cells Cytotoxicity assay 48-72 h Cytotoxicity against human HeLa cells after 48 to 72 hrs by WAT-1 assay, IC50=0.27 μM 21126027
MDR1 cells Cytotoxicity assay 48-72 h Cytotoxicity against human NCI-ADR-RES expressing MDR1 cells after 48 to 72 hrs by WAT-1 assay, IC50=0.29 μM 21126027
Jurkat cells Function assay 24 h Cell cycle arrest in human Jurkat cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis, IC50=0.16 μM 21126027
SW620 cells Cytotoxicity assay 48-72 h Cytotoxicity against human SW620 cells after 48 to 72 hrs by WAT-1 assay, IC50=0.19 μM 21126027
A2780 cells Cytotoxicity assay 48-72 h Cytotoxicity against human A2780 cells after 48 to 72 hrs by WAT-1 assay, IC50=0.17 μM 21126027
HT-29 cells Proliferation assay 72 h Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay, IC50=0.21 μM 23202849
H460 cells Cytotoxicity assay 72 h Cytotoxicity against human H460 cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay, IC50=0.2177 μM 24106982
MKN45 cells Cytotoxicity assay 72 h Cytotoxicity against human MKN45 cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay, IC50=0.166 μM 24106982
HT-29 cells Cytotoxicity assay 72 h Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay, IC50=0.3387 μM 24106982
human A549 cells Cytotoxicity assay 48 h Cytotoxicity against human A549 cells after 48 hrs by MTT assay, IC50=1.31 μM 24835786
ACHN cells Cytotoxicity assay 48 h Cytotoxicity against human ACHN cells after 48 hrs by MTT assay, IC50=2.13 μM 24835786
MCF7 cells Cytotoxicity assay 48 h Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay, IC50=1.25 μM 24835786
HT-29 cells Cytotoxicity assay 48 h Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay, IC50=1.62 μM 24835786
A549 cells Proliferation assay 24 h Antiproliferative activity against human A549 cells assessed as growth inhibition after 24 hrs by SRB assay, GI50=1.31 μM 25468039
human MCF7 cells Proliferation assay 24 h Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 24 hrs by SRB assay, GI50=1.25 μM 25468039
KB-S15 cells Cytotoxicity assay 72 h Cytotoxicity against human KB-S15 cells overexpressing P-gp170/MDR assessed as growth inhibition after 72 hrs by methylene blue staining-based assay, IC50=0.206 μM 24106982
KB-7d cells Cytotoxicity assay 72 h Cytotoxicity against human KB-7d cells overexpressing MRP assessed as growth inhibition after 72 hrs by methylene blue staining-based assay, IC50=0.205 μM 24106982
KB-VIN10 cells Cytotoxicity assay 72 h Cytotoxicity against human KB-VIN10 cells overexpressing P-gp170/MDR assessed as growth inhibition after 72 hrs by methylene blue staining-based assay, IC50=0.227 μM 24106982
human PC3 cells Cytotoxicity assay 48 h Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay, GI50=0.62 μM 26241032
human AsPC1 cells Cytotoxicity assay 48 h Cytotoxicity against human AsPC1 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay, GI50=4.11 μM 26241032
human A549 cells Cytotoxicity assay 48 h Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay, GI50=5.33 μM 26241032
Hep3B cells Cytotoxicity assay 48 h Cytotoxicity against human Hep3B cells assessed as growth inhibition after 48 hrs by sulforhodamine B assay, GI50=0.84 μM 26241032
KB cells Cytotoxicity assay 72 h Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay, IC50=0.2513 μM 24106982
DU145 cells Proliferation assay 24 h Antiproliferative activity against human DU145 cells assessed as growth inhibition after 24 hrs by SRB assay, GI50=1.81 μM 25468039
DU145 cells Cytotoxicity assay 48 h Cytotoxicity against human DU145 cells after 48 hrs by MTT assay, GI50=1.81 μM 24835786
human SKBR3 cells Growth inhibition assay 48 h Growth inhibition of human SKBR3 cells after 48 hrs by MTT assay, IC50=0.74 μM 22850214
HCT-15 cell Proliferation assay Antiproliferative activity against human colon carcinoma HCT-15 cell line(MDR(-)), IC50=0.34 μM 11425534
HCT116-C9 cell Function assay Effective concentration to inhibit cell proliferation by 50% relative to untreated control cell after 72 hr of continuous exposure in HCT116-C9 cell line, IC50=0.9 μM 12383017
NCI-H460 cell Proliferation assay Antiproliferative activity against human lung carcinoma NCI-H460 cell line (MDR(+)), IC50=0.35 μM 11425534
human HL60 cells Proliferation assay Antiproliferative activity against human HL60 cells, IC50=0.34 μM 17276056
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明 ABT-751 (E7010) binds to the colchicine site on β-tubulin and inhibits polymerization of microtubules, not a substrate for the MDR transporter and is active against cell lines resistant to vincristine, doxorubicin, and cisplatin. Phase 1/2.
特性 An orally bioavailable tubulin-binding and antimitotic sulfonamide.
Targets
Microtubules [1]
In Vitro
In vitro In vitro, ABT-751 shows the selective cytotoxicity with IC50 of 0.6–2.6 μM in neuroblastoma and 0.7–4.6 μM in other solid tumor cell lines. Furthermore, ABT-751 also exhibits a selective effect on dynamic microtubules and spares stable microtubules, accounting for the persistence of acetylated and detyrosinated α-tubulin positive polymerized tubules at the IC90 concentration of ABT-751. [1]
細胞実験 細胞株 HOS, HTB-186 Daoy, TC-71, RD, SK-N-AS, SK-N-DZ, LD and KCNR cells
濃度 0 to 100 μM
反応時間 72 hours
実験の流れ Cells, in 1640 RPMI media with FBS, are plated in triplicate onto 96 well tissue culture plates in numbers determined optimal for confluent monolayer growth (5,000 cells/well for HOS, HTB-186 Daoy; 10,000 cells/well for TC-71, RD, SK-N-AS, SK-N-DZ, LD; 30,000 cells/well for KCNR), with an automated, multichannel pipette system. Cells are incubated for 24 hours at 37 °C/5% CO2 then exposed to vehicle control (1.25% DMSO/H2O), VCR (0.1–1000 nM), ABT-751 (0.1 nM–100 μM), and in 4 cell lines (SK-N-AS, KCNR, RD, TC-71) combretastatin (0.1–1000 nM) for 72 hours. Cells are fixed with trichloroacetic acid (final concentration 10%) at 4 °C, washed, then dried at room temperature, stained with SRB in 1% acetic acid and dye is then solubilized with Tris base. Optical density measurements are performed at 540 and 405 nm dual wavelengths in a Bio-Tek EL 340 UV plate reader.
In Vivo
In Vivo In this Calu-6 xenograft model, ABT-751 as a single agent at 100 and 75 mg/kg/day shows significant antitumor activity, while in combination with cisplatin, ABT-751 shows a dose-dependent enhancement in growth delay. In the HT-29 colon xenograft model, ABT-751 also shows significant antitumor activity as a single agent and produced a dose-dependent enhancement in growth delay In combination with 5-FU. [2] In dogs with lymphoma, ABT-751 exhibits the dose-limiting toxicities that included vomiting, diarrhea, anorexia, or some combination of these with a maximum tolerated dose (MTD) of 350 mg/m2 PO q24h. Furthermore, the mean AUC and Cmax for ABT-751 at the MTD of 350 mg/m2 is 5.55 μg-hour/mL and 0.9 μg/mL, respectively. [3]
動物実験 動物モデル Calu-6 NSCLC, HT-29 colon, and HCT-116 cells are injected into athymic mice.
投与量 75 or 100 mg/kg/day
投与経路 Administered via p.o.
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00436852 Completed
Disseminated Neuroblastoma|Recurrent Neuroblastoma
Children''s Oncology Group|National Cancer Institute (NCI)
January 2007 Phase 2
NCT00735878 Terminated
Non Small Cell Lung Cancer|Lung Cancer
Konstantin Dragnev|Abbott|Dartmouth-Hitchcock Medical Center
September 2004 Phase 1|Phase 2

化学情報

分子量 371.41 化学式

C18H17N3O4S

CAS No. 141430-65-1 SDF Download ABT-751 (E7010) SDFをダウンロードする
Smiles COC1=CC=C(C=C1)S(=O)(=O)NC2=C(N=CC=C2)NC3=CC=C(C=C3)O
保管

In vitro
Batch:

DMSO : 74 mg/mL ( (199.24 mM); 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Ethanol : 12 mg/mL

Water : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量 濃度 体積 分子量

投与溶液組成計算機(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)

mg/kg g μL

ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果:

投与溶媒濃度: mg/ml;

DMSOストック溶液調製方法: mg 試薬を μL DMSOに溶解する(濃度 mg/mL, 注:濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法:Take μL DMSOストック溶液に μL PEG300,を加え、完全溶解後μL Tween 80,を加えて完全溶解させた後 μL ddH2O,を加え完全に溶解させます。

投与溶媒調製方法:μL DMSOストック溶液に μL Corn oil,を加え、完全溶解。

注意:1.ストック溶液に沈殿、混濁などがないことをご確認ください;
2.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください
Tags: ABT-751 (E7010)を買う | ABT-751 (E7010) ic50 | ABT-751 (E7010)供給者 | ABT-751 (E7010)を購入する | ABT-751 (E7010)費用 | ABT-751 (E7010)生産者 | オーダーABT-751 (E7010) | ABT-751 (E7010)化学構造 | ABT-751 (E7010)分子量 | ABT-751 (E7010)代理店